| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 58 | 2023 | 680 | 8.400 |
Why?
|
| Cognition | 38 | 2022 | 641 | 6.500 |
Why?
|
| Alzheimer Disease | 41 | 2023 | 800 | 6.300 |
Why?
|
| Cognitive Dysfunction | 27 | 2025 | 449 | 5.620 |
Why?
|
| Brain | 34 | 2023 | 707 | 5.010 |
Why?
|
| Health Literacy | 10 | 2023 | 45 | 4.860 |
Why?
|
| Aged, 80 and over | 102 | 2025 | 2152 | 4.790 |
Why?
|
| Cognition Disorders | 32 | 2019 | 437 | 4.620 |
Why?
|
| Aged | 112 | 2025 | 4000 | 4.430 |
Why?
|
| Decision Making | 11 | 2022 | 95 | 3.830 |
Why?
|
| Female | 115 | 2025 | 6974 | 3.430 |
Why?
|
| Independent Living | 11 | 2025 | 137 | 3.350 |
Why?
|
| Male | 115 | 2025 | 6815 | 3.320 |
Why?
|
| Humans | 138 | 2025 | 12240 | 3.140 |
Why?
|
| Longitudinal Studies | 44 | 2025 | 651 | 3.120 |
Why?
|
| Neuropsychological Tests | 44 | 2022 | 558 | 2.890 |
Why?
|
| Dementia | 14 | 2021 | 236 | 2.710 |
Why?
|
| Cohort Studies | 43 | 2023 | 827 | 2.220 |
Why?
|
| Neurodegenerative Diseases | 6 | 2021 | 60 | 1.990 |
Why?
|
| DNA-Binding Proteins | 9 | 2019 | 151 | 1.770 |
Why?
|
| White Matter | 4 | 2020 | 52 | 1.710 |
Why?
|
| TDP-43 Proteinopathies | 4 | 2021 | 40 | 1.480 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 62 | 1.460 |
Why?
|
| Hippocampus | 7 | 2022 | 97 | 1.430 |
Why?
|
| Financial Management | 2 | 2020 | 6 | 1.250 |
Why?
|
| Neuropathology | 3 | 2020 | 42 | 1.230 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 464 | 1.210 |
Why?
|
| Educational Status | 11 | 2022 | 130 | 1.190 |
Why?
|
| Cognitive Aging | 2 | 2021 | 34 | 1.170 |
Why?
|
| Disease Progression | 14 | 2019 | 290 | 1.120 |
Why?
|
| Literacy | 2 | 2019 | 13 | 1.110 |
Why?
|
| Hospitalization | 3 | 2019 | 158 | 1.100 |
Why?
|
| Cerebral Amyloid Angiopathy | 3 | 2018 | 57 | 1.080 |
Why?
|
| Lewy Bodies | 9 | 2021 | 96 | 1.060 |
Why?
|
| Memory, Episodic | 4 | 2022 | 43 | 1.020 |
Why?
|
| Middle Aged | 38 | 2021 | 4043 | 0.980 |
Why?
|
| Activities of Daily Living | 12 | 2013 | 182 | 0.930 |
Why?
|
| Amyloid beta-Peptides | 4 | 2021 | 98 | 0.900 |
Why?
|
| Motor Activity | 10 | 2015 | 175 | 0.900 |
Why?
|
| Medicare | 2 | 2023 | 59 | 0.800 |
Why?
|
| Government | 1 | 2023 | 2 | 0.800 |
Why?
|
| Prospective Studies | 15 | 2025 | 817 | 0.790 |
Why?
|
| Autopsy | 11 | 2021 | 174 | 0.780 |
Why?
|
| Memory, Short-Term | 3 | 2019 | 53 | 0.730 |
Why?
|
| Life Style | 3 | 2021 | 102 | 0.730 |
Why?
|
| Crime Victims | 1 | 2022 | 16 | 0.730 |
Why?
|
| Blood Glucose | 1 | 2022 | 53 | 0.720 |
Why?
|
| Risk Factors | 22 | 2018 | 1049 | 0.720 |
Why?
|
| Elder Abuse | 1 | 2022 | 19 | 0.710 |
Why?
|
| Perception | 2 | 2019 | 42 | 0.700 |
Why?
|
| Metacognition | 1 | 2021 | 3 | 0.700 |
Why?
|
| Hypertension | 1 | 2022 | 85 | 0.700 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 6 | 0.690 |
Why?
|
| Apolipoprotein E4 | 5 | 2025 | 106 | 0.690 |
Why?
|
| Age of Onset | 1 | 2021 | 46 | 0.680 |
Why?
|
| Age Factors | 14 | 2019 | 350 | 0.670 |
Why?
|
| Economics | 2 | 2018 | 8 | 0.670 |
Why?
|
| Loneliness | 2 | 2020 | 31 | 0.670 |
Why?
|
| Proportional Hazards Models | 12 | 2017 | 161 | 0.650 |
Why?
|
| Limbic Encephalitis | 1 | 2020 | 5 | 0.650 |
Why?
|
| Chronic Disease | 3 | 2017 | 186 | 0.640 |
Why?
|
| Neurofibrillary Tangles | 4 | 2017 | 64 | 0.640 |
Why?
|
| Brain Mapping | 2 | 2018 | 59 | 0.630 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 10 | 0.600 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 60 | 0.600 |
Why?
|
| Dementia, Vascular | 4 | 2018 | 19 | 0.580 |
Why?
|
| Depression | 7 | 2021 | 229 | 0.560 |
Why?
|
| Delay Discounting | 1 | 2018 | 7 | 0.560 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2018 | 29 | 0.540 |
Why?
|
| Learning | 1 | 2018 | 34 | 0.530 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 400 | 0.520 |
Why?
|
| Ambulatory Care | 1 | 2017 | 36 | 0.510 |
Why?
|
| Geriatric Assessment | 5 | 2015 | 96 | 0.500 |
Why?
|
| Residence Characteristics | 5 | 2015 | 87 | 0.500 |
Why?
|
| Agnosia | 1 | 2016 | 3 | 0.490 |
Why?
|
| Nerve Degeneration | 2 | 2014 | 19 | 0.490 |
Why?
|
| Postmortem Changes | 1 | 2016 | 17 | 0.480 |
Why?
|
| Sex Factors | 12 | 2016 | 229 | 0.480 |
Why?
|
| Frail Elderly | 3 | 2014 | 19 | 0.480 |
Why?
|
| Plaque, Amyloid | 2 | 2015 | 45 | 0.470 |
Why?
|
| Memory | 8 | 2018 | 112 | 0.450 |
Why?
|
| Risk-Taking | 2 | 2011 | 18 | 0.430 |
Why?
|
| Temporal Lobe | 3 | 2020 | 29 | 0.430 |
Why?
|
| Mortality | 3 | 2013 | 37 | 0.430 |
Why?
|
| Disabled Persons | 5 | 2013 | 47 | 0.410 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 726 | 0.390 |
Why?
|
| Risk | 6 | 2018 | 97 | 0.380 |
Why?
|
| Choice Behavior | 1 | 2012 | 19 | 0.370 |
Why?
|
| Chicago | 7 | 2025 | 453 | 0.360 |
Why?
|
| Memory Disorders | 4 | 2019 | 68 | 0.350 |
Why?
|
| Sclerosis | 4 | 2020 | 32 | 0.340 |
Why?
|
| Quality of Life | 4 | 2015 | 261 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 182 | 0.330 |
Why?
|
| Surveys and Questionnaires | 8 | 2018 | 546 | 0.330 |
Why?
|
| Adult | 22 | 2018 | 3557 | 0.320 |
Why?
|
| Health Status | 6 | 2019 | 96 | 0.320 |
Why?
|
| Comorbidity | 6 | 2018 | 209 | 0.320 |
Why?
|
| Intention | 1 | 2010 | 9 | 0.310 |
Why?
|
| Income | 4 | 2023 | 35 | 0.310 |
Why?
|
| Goals | 1 | 2010 | 24 | 0.310 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 110 | 0.310 |
Why?
|
| Death | 2 | 2020 | 24 | 0.310 |
Why?
|
| Data Collection | 1 | 2010 | 40 | 0.310 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 108 | 0.300 |
Why?
|
| Risk Assessment | 5 | 2015 | 295 | 0.300 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 26 | 0.300 |
Why?
|
| Brain Infarction | 3 | 2018 | 36 | 0.300 |
Why?
|
| Personality | 2 | 2021 | 18 | 0.270 |
Why?
|
| Time Factors | 9 | 2020 | 695 | 0.270 |
Why?
|
| Caregivers | 3 | 2005 | 95 | 0.260 |
Why?
|
| Prostatic Hyperplasia | 3 | 2003 | 7 | 0.260 |
Why?
|
| Multifactorial Inheritance | 2 | 2018 | 3 | 0.260 |
Why?
|
| Statistics as Topic | 4 | 2017 | 51 | 0.260 |
Why?
|
| Mobility Limitation | 3 | 2015 | 36 | 0.260 |
Why?
|
| United States | 5 | 2023 | 989 | 0.260 |
Why?
|
| Brain Diseases | 2 | 2020 | 30 | 0.250 |
Why?
|
| Incidence | 13 | 2012 | 338 | 0.240 |
Why?
|
| Sex Characteristics | 3 | 2022 | 64 | 0.240 |
Why?
|
| Neurologic Examination | 3 | 2020 | 49 | 0.240 |
Why?
|
| Cerebrovascular Disorders | 3 | 2020 | 60 | 0.230 |
Why?
|
| Self Efficacy | 1 | 2005 | 30 | 0.230 |
Why?
|
| Cerebral Infarction | 3 | 2015 | 63 | 0.230 |
Why?
|
| Cost of Illness | 1 | 2005 | 24 | 0.230 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 423 | 0.220 |
Why?
|
| Parkinsonian Disorders | 1 | 2005 | 91 | 0.210 |
Why?
|
| Muscle Strength | 3 | 2009 | 46 | 0.210 |
Why?
|
| Biomarkers | 3 | 2025 | 294 | 0.210 |
Why?
|
| Self Report | 2 | 2022 | 94 | 0.200 |
Why?
|
| Anxiety Disorders | 2 | 2016 | 84 | 0.200 |
Why?
|
| Disability Evaluation | 5 | 2015 | 105 | 0.200 |
Why?
|
| Urination Disorders | 1 | 2003 | 3 | 0.200 |
Why?
|
| Government Agencies | 1 | 2023 | 2 | 0.200 |
Why?
|
| Mood Disorders | 1 | 2003 | 13 | 0.190 |
Why?
|
| Anisotropy | 2 | 2020 | 25 | 0.190 |
Why?
|
| Mental Recall | 2 | 2020 | 24 | 0.190 |
Why?
|
| Reaction Time | 2 | 2020 | 53 | 0.190 |
Why?
|
| Longevity | 2 | 2013 | 15 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 36 | 0.190 |
Why?
|
| Frontal Lobe | 2 | 2018 | 32 | 0.190 |
Why?
|
| Linear Models | 3 | 2018 | 115 | 0.190 |
Why?
|
| Fraud | 1 | 2022 | 6 | 0.190 |
Why?
|
| Motor Skills | 2 | 2013 | 32 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 1 | 2022 | 40 | 0.180 |
Why?
|
| Urinary Retention | 2 | 2003 | 8 | 0.180 |
Why?
|
| Lewy Body Disease | 3 | 2018 | 54 | 0.180 |
Why?
|
| Blood Pressure | 1 | 2022 | 99 | 0.180 |
Why?
|
| Mental Disorders | 2 | 2018 | 62 | 0.180 |
Why?
|
| Reference Values | 2 | 2020 | 103 | 0.180 |
Why?
|
| Executive Function | 1 | 2021 | 47 | 0.170 |
Why?
|
| Psychomotor Performance | 2 | 2019 | 85 | 0.170 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 20 | 0.170 |
Why?
|
| Demography | 2 | 2018 | 37 | 0.170 |
Why?
|
| Prognosis | 3 | 2017 | 363 | 0.160 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 12 | 0.160 |
Why?
|
| Serial Learning | 1 | 2020 | 4 | 0.160 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 2 | 2010 | 19 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 153 | 0.160 |
Why?
|
| Frailty | 1 | 2020 | 6 | 0.160 |
Why?
|
| Space Perception | 1 | 2019 | 10 | 0.150 |
Why?
|
| Self Concept | 1 | 2020 | 26 | 0.150 |
Why?
|
| Awareness | 2 | 2016 | 21 | 0.150 |
Why?
|
| Illinois | 2 | 2017 | 110 | 0.150 |
Why?
|
| Mouth Neoplasms | 3 | 1997 | 9 | 0.150 |
Why?
|
| Regression Analysis | 6 | 2013 | 105 | 0.140 |
Why?
|
| Models, Statistical | 2 | 1998 | 60 | 0.140 |
Why?
|
| Pain | 2 | 2010 | 193 | 0.140 |
Why?
|
| Emergencies | 1 | 2019 | 26 | 0.140 |
Why?
|
| Computer Graphics | 1 | 1998 | 3 | 0.140 |
Why?
|
| Alcohol Drinking | 4 | 1996 | 28 | 0.140 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 10 | 0.140 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2018 | 14 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 97 | 0.130 |
Why?
|
| Finasteride | 1 | 1997 | 2 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 157 | 0.130 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 3 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 75 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2017 | 93 | 0.130 |
Why?
|
| Personality Development | 1 | 2016 | 2 | 0.120 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 11 | 0.120 |
Why?
|
| Laryngeal Neoplasms | 1 | 1996 | 12 | 0.120 |
Why?
|
| Affect | 1 | 2016 | 29 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 23 | 0.120 |
Why?
|
| Fetus | 1 | 2016 | 20 | 0.120 |
Why?
|
| Intelligence | 1 | 2016 | 10 | 0.120 |
Why?
|
| Comprehension | 1 | 2016 | 11 | 0.120 |
Why?
|
| Brain Chemistry | 1 | 2016 | 22 | 0.120 |
Why?
|
| Survival Rate | 2 | 2012 | 152 | 0.120 |
Why?
|
| Apolipoproteins E | 2 | 2013 | 100 | 0.120 |
Why?
|
| Vascular Diseases | 2 | 2013 | 25 | 0.120 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 55 | 0.110 |
Why?
|
| Organ Size | 1 | 2015 | 41 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 125 | 0.110 |
Why?
|
| Sex Distribution | 4 | 2012 | 34 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 48 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 100 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1994 | 4 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 218 | 0.100 |
Why?
|
| Psychometrics | 2 | 2014 | 95 | 0.100 |
Why?
|
| Mesencephalon | 1 | 2013 | 13 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 1994 | 35 | 0.100 |
Why?
|
| Causality | 3 | 2012 | 22 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 8 | 0.100 |
Why?
|
| Neuroticism | 3 | 2021 | 13 | 0.100 |
Why?
|
| Retinoids | 1 | 1992 | 4 | 0.090 |
Why?
|
| Leukoplakia, Oral | 1 | 1992 | 2 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 12 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 1992 | 8 | 0.090 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2012 | 19 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2012 | 32 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 1 | 1992 | 4 | 0.090 |
Why?
|
| Financing, Personal | 1 | 2012 | 3 | 0.090 |
Why?
|
| Neurons | 1 | 2013 | 164 | 0.090 |
Why?
|
| Models, Psychological | 1 | 2012 | 37 | 0.090 |
Why?
|
| Connecticut | 5 | 2002 | 6 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2011 | 23 | 0.090 |
Why?
|
| Adolescent | 6 | 2018 | 989 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2014 | 112 | 0.090 |
Why?
|
| England | 2 | 2003 | 8 | 0.090 |
Why?
|
| Social Participation | 1 | 2011 | 4 | 0.080 |
Why?
|
| Child | 5 | 2013 | 614 | 0.080 |
Why?
|
| Logistic Models | 5 | 2016 | 196 | 0.080 |
Why?
|
| Social Behavior | 1 | 2011 | 38 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2002 | 256 | 0.080 |
Why?
|
| Knowledge | 1 | 2010 | 7 | 0.080 |
Why?
|
| Beer | 1 | 1990 | 2 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 1990 | 3 | 0.080 |
Why?
|
| Language | 1 | 2010 | 30 | 0.080 |
Why?
|
| Diet | 4 | 1996 | 104 | 0.080 |
Why?
|
| Housing for the Elderly | 1 | 2010 | 5 | 0.080 |
Why?
|
| tau Proteins | 2 | 2025 | 88 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 1990 | 47 | 0.080 |
Why?
|
| Urban Population | 1 | 2010 | 78 | 0.080 |
Why?
|
| Lung | 1 | 2009 | 76 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2009 | 26 | 0.070 |
Why?
|
| Kidney | 1 | 2009 | 87 | 0.070 |
Why?
|
| France | 2 | 2003 | 9 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2002 | 195 | 0.070 |
Why?
|
| Alleles | 3 | 2015 | 119 | 0.070 |
Why?
|
| Hand Strength | 1 | 2007 | 24 | 0.070 |
Why?
|
| Leg | 1 | 2007 | 16 | 0.060 |
Why?
|
| Observation | 1 | 2007 | 5 | 0.060 |
Why?
|
| Smoking | 4 | 1996 | 84 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2013 | 320 | 0.060 |
Why?
|
| United Kingdom | 2 | 2016 | 23 | 0.060 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 18 | 0.060 |
Why?
|
| Interview, Psychological | 1 | 2005 | 17 | 0.060 |
Why?
|
| Mental Status Schedule | 1 | 2005 | 38 | 0.060 |
Why?
|
| Home Nursing | 1 | 2005 | 13 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2025 | 30 | 0.060 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 12 | 0.060 |
Why?
|
| Gait | 1 | 2007 | 195 | 0.060 |
Why?
|
| Heterozygote | 2 | 2015 | 72 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 169 | 0.050 |
Why?
|
| Korea | 1 | 2003 | 6 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 73 | 0.050 |
Why?
|
| Netherlands | 1 | 2003 | 23 | 0.050 |
Why?
|
| Azasteroids | 1 | 2003 | 2 | 0.050 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2003 | 2 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 151 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 42 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 47 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 863 | 0.050 |
Why?
|
| Hair Dyes | 1 | 2002 | 1 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 118 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2012 | 221 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 4 | 0.040 |
Why?
|
| Neoplasms | 1 | 2003 | 94 | 0.040 |
Why?
|
| Individuality | 1 | 2021 | 11 | 0.040 |
Why?
|
| Scotland | 2 | 1998 | 2 | 0.040 |
Why?
|
| Infant | 3 | 2003 | 277 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2003 | 312 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2000 | 58 | 0.040 |
Why?
|
| Age Distribution | 2 | 1997 | 25 | 0.040 |
Why?
|
| Exercise | 2 | 2012 | 233 | 0.040 |
Why?
|
| Registries | 2 | 1997 | 88 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2002 | 115 | 0.040 |
Why?
|
| Wales | 1 | 1998 | 4 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1998 | 12 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1998 | 16 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2018 | 25 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 17 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 23 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 17 | 0.030 |
Why?
|
| Gingival Neoplasms | 1 | 1997 | 1 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2003 | 247 | 0.030 |
Why?
|
| Acute Disease | 1 | 1997 | 90 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1996 | 5 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 3 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 1996 | 8 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1996 | 3 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 1996 | 11 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1996 | 5 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 9 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 128 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Arteriolosclerosis | 1 | 2016 | 25 | 0.030 |
Why?
|
| Time | 1 | 1996 | 10 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1996 | 15 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 252 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 1994 | 61 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 132 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 9 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 10 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2016 | 27 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 47 | 0.030 |
Why?
|
| Vitamin A | 2 | 1993 | 5 | 0.030 |
Why?
|
| Brain Stem | 1 | 2016 | 7 | 0.030 |
Why?
|
| Carotenoids | 2 | 1993 | 7 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 36 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 157 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 45 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 77 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 15 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 21 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 18 | 0.030 |
Why?
|
| Carcinoma | 1 | 1994 | 34 | 0.030 |
Why?
|
| New South Wales | 1 | 1994 | 1 | 0.030 |
Why?
|
| Raphe Nuclei | 1 | 2013 | 5 | 0.030 |
Why?
|
| Locus Coeruleus | 1 | 2013 | 6 | 0.030 |
Why?
|
| Ventral Tegmental Area | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 38 | 0.030 |
Why?
|
| Fathers | 1 | 1994 | 15 | 0.030 |
Why?
|
| Lip Neoplasms | 1 | 1993 | 2 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 324 | 0.020 |
Why?
|
| Depressive Disorder | 2 | 2007 | 90 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2013 | 68 | 0.020 |
Why?
|
| Pregnancy | 1 | 1994 | 193 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 24 | 0.020 |
Why?
|
| Developing Countries | 1 | 1993 | 7 | 0.020 |
Why?
|
| Animals | 1 | 1998 | 2092 | 0.020 |
Why?
|
| Isotretinoin | 1 | 1992 | 5 | 0.020 |
Why?
|
| Poland | 1 | 1992 | 2 | 0.020 |
Why?
|
| Coffee | 1 | 1992 | 3 | 0.020 |
Why?
|
| Energy Intake | 1 | 1992 | 46 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 23 | 0.020 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1992 | 1 | 0.020 |
Why?
|
| Mental Health | 1 | 2012 | 47 | 0.020 |
Why?
|
| Health Behavior | 1 | 2012 | 74 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2011 | 5 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 45 | 0.020 |
Why?
|
| Nerve Net | 1 | 2011 | 22 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1992 | 30 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 24 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 26 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1992 | 59 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 14 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1991 | 6 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 72 | 0.020 |
Why?
|
| Social Support | 1 | 2011 | 98 | 0.020 |
Why?
|
| Italy | 1 | 1990 | 4 | 0.020 |
Why?
|
| Switzerland | 1 | 1990 | 5 | 0.020 |
Why?
|
| Wine | 1 | 1990 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 1991 | 175 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2009 | 13 | 0.020 |
Why?
|
| Microcirculation | 1 | 2009 | 15 | 0.020 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1989 | 1 | 0.020 |
Why?
|
| Atrophy | 1 | 2009 | 29 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 26 | 0.020 |
Why?
|
| Europe | 2 | 2003 | 21 | 0.020 |
Why?
|
| Catholicism | 1 | 2007 | 7 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2007 | 12 | 0.020 |
Why?
|
| Clergy | 1 | 2007 | 39 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2003 | 1467 | 0.010 |
Why?
|
| Dutasteride | 1 | 2003 | 2 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 46 | 0.010 |
Why?
|
| Death Certificates | 1 | 2003 | 1 | 0.010 |
Why?
|
| World Health Organization | 1 | 2003 | 3 | 0.010 |
Why?
|
| Color | 1 | 2002 | 6 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 8 | 0.010 |
Why?
|
| Hawaii | 1 | 2000 | 1 | 0.010 |
Why?
|
| Japan | 1 | 2000 | 2 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 1478 | 0.010 |
Why?
|
| Cohort Effect | 1 | 1994 | 1 | 0.010 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 1994 | 2 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1994 | 24 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 70 | 0.010 |
Why?
|
| Cardia | 1 | 1993 | 2 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 1993 | 2 | 0.010 |
Why?
|
| Hernia, Hiatal | 1 | 1993 | 6 | 0.010 |
Why?
|
| Edible Grain | 1 | 1993 | 1 | 0.010 |
Why?
|
| Trace Elements | 1 | 1993 | 2 | 0.010 |
Why?
|
| Seafood | 1 | 1993 | 7 | 0.010 |
Why?
|
| Phosphorus | 1 | 1993 | 4 | 0.010 |
Why?
|
| Vitamins | 1 | 1993 | 9 | 0.010 |
Why?
|
| Iron | 1 | 1993 | 13 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1993 | 8 | 0.010 |
Why?
|
| Diet Surveys | 1 | 1993 | 12 | 0.010 |
Why?
|
| Vegetables | 1 | 1993 | 14 | 0.010 |
Why?
|
| Fruit | 1 | 1993 | 18 | 0.010 |
Why?
|
| China | 1 | 1993 | 25 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1993 | 40 | 0.010 |
Why?
|
| Pleural Neoplasms | 1 | 1992 | 4 | 0.010 |
Why?
|
| Calcium | 1 | 1993 | 288 | 0.000 |
Why?
|
| Cause of Death | 1 | 1989 | 32 | 0.000 |
Why?
|